Results 161 to 170 of about 436,511 (214)

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial. [PDF]

Hum Vaccin Immunother
Perroud A, Madruga JVR, Fernandes L, Luz K, Lukic N, Bourée S, Sanchez-Ruiz M, Pegoraro F, Petit C, Zambrano B, Dayan G.   +10 more
europepmc   +1 more source

Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome. [PDF]

J Invest Dermatol
Strother C, Bouffard N, Smolynets O, Graham NR, Elko EA, Sabundayo B, Durbin AP, Whitehead SS, Taatjes DJ, Kirkpatrick BD, Greene L, Pierce KK, Diehl SA.   +12 more
europepmc   +1 more source

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children. [PDF]

NPJ Vaccines
Mandaric S, Friberg H, Saez-Llorens X, Borja-Tabora C, Biswal S, Escudero I, Faccin A, Gottardo R, Brose M, Roubinis N, Fladager D, DeAntonio R, Dimero JAL, Montenegro N, Folschweiller N, Currier JR, Sharma M, Tricou V.   +17 more
europepmc   +1 more source

Travel medicine providers' opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan. [PDF]

Hum Vaccin Immunother
Fukunishi A, Machida M, Fukushima S, Inoue S.   +3 more
europepmc   +1 more source

Knowledge, attitude, and practice regarding dengue vaccine: a baseline study of community members and health providers in Indonesia. [PDF]

Clin Exp Pediatr
Wahab A, Laksanawati IS, Padmawati RS, Mulyadi AWE, Triadmajani W, Thobari JA.   +5 more
europepmc   +1 more source

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience. [PDF]

PLoS Negl Trop Dis
Fernando L, Kastner R, Wickramasinghe P, Fernando AD, Gunasekera D, Nguyen VH, Liu M, LeFevre I, Wallace D, Folschweiller N, Biswal S.   +10 more
europepmc   +1 more source

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination. [PDF]

J Infect Dis
Sirivichayakul C, Biswal S, Saez-Llorens X, López-Medina E, Borja-Tabora C, Bravo L, Kosalaraksa P, Alera MT, Reynales H, Rivera L, Watanaveeradej V, Yu D, Espinoza F, Dietze R, Fernando L, Wickramasinghe VP, Moreira ED, Fernando AD, Gunasekera D, Luz K, Venâncio da Cunha R, Oliveira AL, Rauscher M, Fan H, Borkowski A, Escudero I, Tuboi S, Lloyd E, Tricou V, Folschweiller N, LeFevre I, Vargas LM, Wallace D, TIDES Study Group .   +33 more
europepmc   +1 more source

Delivering safe dengue vaccines

The Lancet Global Health
openaire   +2 more sources

Correction to: Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group. [PDF]

Clin Infect Dis
europepmc   +1 more source